keyword
MENU ▼
Read by QxMD icon Read
search

arthritis rheumatoides

keyword
https://www.readbyqxmd.com/read/29692005/an-extension-study-of-pf-05280586-a-potential-rituximab-biosimilar-versus-rituximab-in-subjects-with-active-rheumatoid-arthritis
#1
Stanley B Cohen, Rubén Burgos-Vargas, Paul Emery, Bo Jin, Carol Cronenberger, María-Dolores Vázquez-Abad
OBJECTIVE: This extension study provided continued treatment to subjects with active rheumatoid arthritis who had participated for ≥16 weeks in a pharmacokinetic similarity study of PF-05280586 (potential rituximab biosimilar). Objectives were to evaluate overall pharmacokinetics, pharmacodynamics, immunogenicity, safety, and tolerability of PF-05280586 after transition from a licensed rituximab product to PF-05280586, and followup of biomarker and efficacy assessments. METHODS: Subjects were offered ≤3 additional courses of treatment of PF-05280586, with or without a single transition from rituximab EU (rituximab-EU) or US (rituximab-US) to PF-05280586...
April 25, 2018: Arthritis Care & Research
https://www.readbyqxmd.com/read/29691998/a-novel-method-to-combine-assessment-of-benefit-and-harm-omeract-3x3-methodology-applied-to-two-active-comparator-trials
#2
Maarten Boers, Jasvinder A Singh, Stacey S Cofield, S Louis Bridges, Larry W Moreland, James R O'Dell, Hongsheng Wu, Sarah Leatherman, Jeffrey R Curtis
INTRODUCTION: The Outcome Measures in Rheumatology (OMERACT) '3x3' method analyzes the occurrence of benefit and harm simultaneously at the individual patient level. We applied this method to two recent rheumatoid arthritis (RA) trial datasets. METHODS: Treatment of Early Aggressive RA (TEAR) and the RA Comparison of Active Therapies (RACAT) randomized trial outcomes for safety were defined according to OMERACT as no events, non-serious events, and serious events...
April 25, 2018: Arthritis Care & Research
https://www.readbyqxmd.com/read/29691971/hydroxychloroquine-may-be-associated-with-reduced-risk-of-coronary-artery-diseases-in-patients-with-rheumatoid-arthritis-a-nationwide-population-based-cohort-study
#3
Yao-Min Hung, Yu-Hsun Wang, Lichi Lin, Paul Yung Pou Wang, Jeng-Yuan Chiou, James Cheng-Chung Wei
OBJECTIVES: The aim of this study was to determine whether hydroxychloroquine (HCQ) usage is associated with incidental risk of coronary artery diseases (CAD) in patients with rheumatoid arthritis (RA). METHODS: The Longitudinal Health Insurance Database in Taiwan was used. The study cohort comprised of 1104 newly diagnosed RA patients between 2001-2010, and patients were followed until 31 December 2011. Patients with history of CAD before RA diagnosis were excluded...
April 24, 2018: International Journal of Clinical Practice
https://www.readbyqxmd.com/read/29691690/-biomarkers-and-imaging-for-diagnosis-and-stratification-of-rheumatoid-arthritis-and-spondylarthritis-in-the-bmbf-consortium-arthromark
#4
REVIEW
T Häupl, A Skapenko, B Hoppe, K Skriner, H Burkhardt, D Poddubnyy, S Ohrndorf, P Sewerin, U Mansmann, B Stuhlmüller, H Schulze-Koops, G-R Burmester
Rheumatic diseases are among the most common chronic inflammatory disorders. Besides severe pain and progressive destruction of the joints, rheumatoid arthritis (RA), spondyloarthritides (SpA) and psoriatic arthritis (PsA) impair working ability, reduce quality of life and if treated insufficiently may enhance mortality. With the introduction of biologics to treat these diseases, the demand for biomarkers of early diagnosis and therapeutic stratification has been growing continuously. The main goal of the consortium ArthroMark is to identify new biomarkers and to apply modern imaging technologies for diagnosis, follow-up assessment and stratification of patients with RA, SpA and PsA...
April 24, 2018: Zeitschrift Für Rheumatologie
https://www.readbyqxmd.com/read/29691687/-characteristics-of-pharmacotherapy-in-older-patients-with-rheumatism
#5
REVIEW
H-J Lakomek, Christian Schulz
Due to medical advances and the availability of efficient immunosuppressive therapies, the life-expectancy of people suffering from inflammatory rheumatic diseases is continuously increasing. In Germany, geriatric patients (definition: age older than 70 years combined with geriatric multimorbidity) affected, e. g. by rheumatoid arthritis (RA) frequently receive corticosteroids and less often biologic disease-modifying antirheumatic drugs (bDMARDs) and conventional DMARDs (cDMARDs), which is justified by additionally existing comorbidities and polypharmacy...
April 24, 2018: Zeitschrift Für Rheumatologie
https://www.readbyqxmd.com/read/29691685/adherence-and-health-literacy-as-related-to-outcome-of-patients-treated-for-rheumatoid-arthritis-analyses-of-a-large-scale-observational-study
#6
J G Kuipers, M Koller, F Zeman, K Müller, J U Rüffer
BACKGROUND: Disabilities in daily living and quality of life are key endpoints for evaluating the treatment outcome for rheumatoid arthritis (RA). Factors possibly contributing to good outcome are adherence and health literacy. METHODS: The survey included a representative nationwide sample of German rheumatologists and their patients with RA. The physician questionnaire included the disease activity score (DAS28) and medical prescriptions. The patient questionnaire included fatigue (EORTC QLQ-FA13), health assessment questionnaire (HAQ), quality of life (SF-12), health literacy (HELP), and patients' listings of their medications...
April 24, 2018: Zeitschrift Für Rheumatologie
https://www.readbyqxmd.com/read/29691581/-upregulation-of-mir-498-suppresses-th17-cell-differentiation-by-targeting-stat3-in-rheumatoid-arthritis-patients
#7
Hai-Yan Xiang, Feng Pan, Ju-Zhen Yan, Li-Quan Hong, La-Hong Zhang, Yu-Hua Liu, Xiao Feng, Cheng-Song Cai
To investigate the effect and mechanism of miR-498 on Th17 cell differentiation of peripheral blood mononuclear cells (PMBCs) in rheumatoid arthritis (RA) patients, peripheral blood samples were collected from RA patients and healthy controls, respectively. The proportion of CD4+ IL-17+ T cells (Th17 cells) or CD4+ FOXP3+ T cells (Tregs) in T cells and the Th17/Treg ratio were identified by the flow cytometer. The STAT3 and miR-498 expression were measured by Western blot and real-time PCR, respectively. ELISA was used to detect IL-17 concentrations...
April 25, 2018: Sheng Li Xue Bao: [Acta Physiologica Sinica]
https://www.readbyqxmd.com/read/29691361/salvianolic-acid-b-suppresses-inflammatory-mediator-levels-by-downregulating-nf-%C3%AE%C2%BAb-in-a-rat-model-of-rheumatoid-arthritis
#8
Zeng-Bing Xia, Yong-Jian Yuan, Qiang-Hua Zhang, Heng Li, Ji-Lin Dai, Ji-Kang Min
BACKGROUND Salvianolic acid B (SB) is a major active phyto-component of the plant Radix Salvia miltiorrhiza, which is traditionally used to treat joint pain and arthritis. The present study examined the anti-rheumatoid arthritis efficacy of SB on collagen-induced rheumatoid arthritis (CIA) in a rat model. MATERIAL AND METHODS Forty-eight rats were divided into 4 groups: Control rats treated with saline (Group I), rats subjected to CIA induction by intradermal injection of bovine collagen II type at the tail (Group II), and rats subjected to CIA and supplemented with either 20 or 40 mg/kg of SB for 28 days (group III or IV)...
April 25, 2018: Medical Science Monitor: International Medical Journal of Experimental and Clinical Research
https://www.readbyqxmd.com/read/29691171/risk-adjustment-is-necessary-in-medicare-bundled-payment-models-for-total-hip-and-knee-arthroplasty
#9
P Maxwell Courtney, Daniel D Bohl, Edmund C Lau, Kevin L Ong, Joshua J Jacobs, Craig J Della Valle
BACKGROUND: Concerns exist that high-risk patients in alternative payment models may face difficulties with access to care without proper risk adjustment. The purpose of this study is to identify the effect of medical and orthopedic specific risk factors on the cost of a 90-day episode of care following total hip (THA) and knee arthroplasty (TKA). METHODS: We queried the Medicare 5% Limited Data Set for all patients undergoing primary THA and TKA from 2010 to 2014...
March 17, 2018: Journal of Arthroplasty
https://www.readbyqxmd.com/read/29691058/er-stress-a-therapeutic-target-in-rheumatoid-arthritis
#10
REVIEW
Marveh Rahmati, Mohammad Amin Moosavi, Michael F McDermott
Diverse physiological and pathological conditions that impact on protein folding of the endoplasmic reticulum (ER) cause ER stress. The unfolded protein response (UPR) and the ER-associated degradation (ERAD) pathway are activated to cope with ER stress. In rheumatoid arthritis (RA), inflammation and ER stress work in parallel by driving inflammatory cells to release cytokines that induce chronic ER stress pathways. This chronic ER stress may contribute to the pathogenesis of RA through synoviocyte proliferation and proinflammatory cytokine production...
April 22, 2018: Trends in Pharmacological Sciences
https://www.readbyqxmd.com/read/29690863/il-20-bone-diseases-involvement-and-therapeutic-target-potential
#11
REVIEW
Hsiao-Hsuan Wang, Yu-Hsiang Hsu, Ming-Shi Chang
BACKGROUND: Millions of people around the world suffer from bone disorders, likes osteoporosis, rheumatoid arthritis (RA), and cancer-induced osteolysis. In general, the bone remodeling balance is determined by osteoclasts and osteoblasts, respectively responsible for bone resorption and bone formation. Excessive inflammation disturbs the activities of these two kinds of cells, typically resulting in the bone loss. MAIN BODY: IL-20 is emerging as a potent angiogenic, chemotactic, and proinflammatory cytokine related to several chronic inflammatory disorders likes psoriasis, atherosclerosis, cancer, liver fibrosis, and RA...
April 24, 2018: Journal of Biomedical Science
https://www.readbyqxmd.com/read/29690734/-effect-of-dishevelled-2-on-apoptosis-in-rheumatoid-arthritis-fibroblast-like-synoviocytes-through-inhibiting-jak-stat-pathway
#12
X Z Liu, Y Gao, C H Zhu, K Qi, X Xu, D B Zhao
Objective: To investigate if Dishevelled 2 (DVL2) regulates the apoptosis of rheumatoid arthritis fibroblast-like synoviocytes (RA-FLS) via the JAK-STAT pathway. Methods: DVL2 overexpressed lentivirus was transfected into RA-FLS and the apoptosis rate was detected by flow cytometry. The effect of DVL2 on RA-FLS signaling pathway was detected by RNA-seq, and then the key genes were verified by RT-PCR. Results: Compared with the control group, DVL2 significantly increased the apoptosis rate of MH7A (3.2%±2.2% vs 25...
April 17, 2018: Zhonghua Yi Xue za Zhi [Chinese medical journal]
https://www.readbyqxmd.com/read/29688897/frequency-and-predictors-of-communication-about-high-blood-pressure-in-rheumatoid-arthritis-visits
#13
Christie Michels Bartels, Heather Johnson, Katya Alcaraz Voelker, Alexis Ogdie, Patrick McBride, Elizabeth A Jacobs, Ying-Qi Zhao, Maureen Smith
BACKGROUND/OBJECTIVE: Given heightened cardiovascular disease (CVD) risk in rheumatoid arthritis (RA) and that higher blood pressure (BP) represents greater CVD risk, we hypothesized that higher BP would predict more BP-related communication in rheumatology visits. We examined predictors of documented BP communication during RA clinic visits. METHODS: This was a retrospective cohort study of RA patients identified in electronic health record records with uncontrolled hypertension (HTN) receiving both primary and rheumatology care...
April 24, 2018: Journal of Clinical Rheumatology: Practical Reports on Rheumatic & Musculoskeletal Diseases
https://www.readbyqxmd.com/read/29688617/pharmacokinetics-of-upadacitinib-with-the-clinical-regimens-of-the-extended-release-formulation-utilized-in-rheumatoid-arthritis-phase-3-trials
#14
Mohamed-Eslam F Mohamed, Jiewei Zeng, Patrick J Marroum, In-Ho Song, Ahmed A Othman
Upadacitinib is a Janus kinase 1 inhibitor under development for the treatment of several inflammatory disorders including rheumatoid arthritis (RA). Upadacitinib was administered in the phase 2 RA trials primarily as twice-daily regimens of an immediate-release (IR) formulation. The upadacitinib extended-release (ER) formulation was developed to enable once-daily dosing. In the present study, upadacitinib pharmacokinetics were characterized after the administration of single and multiple once-daily doses of the ER formulation in healthy subjects relative to single and multiple twice-daily doses of the IR formulation...
April 24, 2018: Clinical Pharmacology in Drug Development
https://www.readbyqxmd.com/read/29688550/is-remission-achievable-in-most-patients-with-rheumatoid-arthritis-results-suggest-not
#15
Marwan Bukhari
No abstract text is available yet for this article.
April 20, 2018: Rheumatology
https://www.readbyqxmd.com/read/29688503/the-potential-benefits-of-aspirin-for-primary-cardiovascular-prevention-in-rheumatoid-arthritis-a-secondary-analysis-of-the-precision-trial
#16
Daniel H Solomon, Peter Libby, Neville D Yeomans, Qiuqing Wang, Kathy E Wolski, Steven E Nissen, M Elaine Husni
Objective: Guidelines exist for the use of low-dose aspirin in the general population for primary cardiovascular (CV) prevention, but the risk-benefit considerations may differ in RA. While RA confers an increased CV risk, such patients more likely use NSAIDs and corticosteroids. Methods: We conducted a cohort study to assess potential risks and benefits of low-dose aspirin. We estimated incidence rates and hazard ratios (HRs) using Cox regression among subjects with RA but no known CV disease in the Prospective Randomized Evaluation of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen trial...
April 20, 2018: Rheumatology
https://www.readbyqxmd.com/read/29687872/ikk%C3%AE%C2%B5-aggravates-inflammatory-response-via-phosphorylation-of-erk-in-rheumatoid-arthritis
#17
L-F Zhou, W Zeng, L-C Sun, Y Wang, F Jiang, X Li, Y Zheng, G-M Wu
OBJECTIVE: Rheumatoid Arthritis (RA) is a chronic systemic autoimmune disease, whereas its cause still remains elusive. Typical pathological manifestations of RA include persistent synovitis and bone degeneration in the surrounding joints. Although the incidence of RA is high in population, currently there have been no effective cures for it. The purpose of this study is to investigate the therapeutic effects and main mechanism of IKKε (inhibitor of nuclear factor kappa-B kinase ε) in collagen II induced- Rheumatoid Arthritis (CIA) mice model...
April 2018: European Review for Medical and Pharmacological Sciences
https://www.readbyqxmd.com/read/29687787/drug-induced-thrombotic-microangiopathy-with-certolizumab-pegol
#18
Mehmet Baysal, Elif Gülsüm Ümit, Fatih Sarıtaş, Nil Su Kodal, Ahmet Muzaffer Demir
BACKGROUND: Certolizumab pegol is used to treat ankylosing spondylitis (AS), chron disease, psoriatic arthritis and rheumatoid arthritis. In contrast to other monoclonal antibodies such as infliximab and adalimumab, certolizumab does not contain an Fc fraction and hence, does not induce complement activation. In this case, we are presenting a case with thrombotic microangiopathy (TMA) due to certolizumab pegol, with a touch of pathophysiological approach to TMA. CASE REPORT: A-39-year-old man with AS of ten years presented with fatigue...
April 24, 2018: Balkan Medical Journal
https://www.readbyqxmd.com/read/29687421/baricitinib-a-review-in-rheumatoid-arthritis
#19
Zaina T Al-Salama, Lesley J Scott
Baricitinib (Olumiant® ) is an oral, targeted synthetic DMARD that inhibits JAK1 and JAK2, which are implicated in the pathogenesis of rheumatoid arthritis (RA). This novel, small molecule is approved for use as monotherapy, or in combination with methotrexate, for the treatment of adults with moderate to severe active RA who responded inadequately to or were intolerant of ≥ 1 DMARD. In pivotal multinational trials, once-daily baricitinib 4 mg, with/without methotrexate (± another csDMARD), improved the signs and symptoms of RA, disease activity and physical function in DMARD-naive patients and in patients with an inadequate response to methotrexate, csDMARDs or TNF inhibitors; baricitinib treatment also slowed structural joint damage in DMARD-naive patients and in those with an inadequate response to methotrexate and csDMARDs...
April 23, 2018: Drugs
https://www.readbyqxmd.com/read/29686987/recognition-and-relevance-of-anti-dfs70-autoantibodies-in-routine-antinuclear-autoantibodies-testing-at-a-community-hospital
#20
John B Carter, Sara Carter, Sandra Saschenbrecker, Bruce E Goeckeritz
Antinuclear autoantibodies (ANA) displaying a dense fine speckled pattern (DFS, ICAP AC-2) on HEp-2 cells are frequently observed in clinical laboratory referrals, often associated with anti-DFS70 specificity. Anti-DFS70 positive patients rarely develop systemic autoimmune rheumatic disease (SARD), especially in the absence of clinical evidence or additional anti-extractable nuclear antigen (ENA) antibodies, prompting suggestions that an isolated DFS70-specific ENA may be an exclusionary finding for SARD. In this study, the frequency and diagnostic significance of anti-DFS70 autoantibodies was investigated in a community hospital cohort of patients undergoing routine ANA testing...
2018: Frontiers in Medicine
keyword
keyword
52109
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"